Skip to main content

Biofrontera Value Stock - Dividend - Research Selection

Biofrontera

ISIN: DE0006046113, WKN: 604611

Market price date: 21.09.2020
Market price: 3,51 EUR




Biofrontera Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 27-04-2020
Cash flow
Net operating cash flow -32.894.000
Capital Expenditures -1.854.000
Free cash flow -34.748.000
Balance sheet
Total Equity 9.955.000
Liabilities & Shareholders equity 58.363.000
Income statement
Net income -7.644.000
Eps (diluted) -0,165
Diluted shares outstanding 46.327.300
Net sales/revenue 31.265.000

Fundamental ratios calculated on: 21-09-2020

Ratios
Key figures 21-09-2020
Cash flow
P/C -4,94
   
P/FC -4,68
Balance sheet
ROI-13,10
ROE17,06
Income statement
P/E-21,27
Div. Yield0,00%
P/B16,33
P/S5,20


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolB8F.XETRA
Market Capitalization199.663.696,00 USD
CountryGermany
IndicesCDAX,Prime All Share
SectorsChemistry
Raw Data SourceIFRS in Millionen EUR
Stock Split2018-01-30,465.000000/443.000000; 2016-04-05,1779.000000/1759.000000; 2015-10-28,43.000000/42.000000; 2012-03-08,121.000000/114.000000; 2009-03-24,1.000000/1.000000
Internetwww.biofrontera.com


Description of the company

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of mild to moderate acne. The company offers its products primarily in the United States, Europe, and Israel. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.biofrontera.com